Phase I Study Demonstrates Safety and Tolerability of Radiofrequency Ablation (RFA) of the Anal Mucosa
- 1 February 2014
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 15 (1) , 36-44
Abstract
Background: Anal carcinoma is increasing in high-risk populations. Dysplasia is often distributed throughout the anal mucosa, and focal ablative techniques have high rates of recurrence. Methods: With the goal of eradicating dysplasia from the entire anal mucosa, we conducted a phase I dose-ranging study to determine the safety and tolerability of radiofrequency ablation (RFA). HIV-infected individuals with high-grade anal intraepithelial neoplasia underwent RFA of the anal mucosa. Patient-reported procedural and postprocedural symptoms were recorded, and mucosal healing was visually assessed. Results: Four groups of 3 subjects each were treated with incrementally increasing numbers of RF pulses (1-3) applied to a single area of anal mucosa. Two or three doses of 12 J/cm2 were found to have acceptable patient tolerance and healing of the mucosa within 4 weeks of ablation. Using these doses, 2 groups underwent ablation of 180° of contiguous mucosa. Subjects experienced a loss of 1 to 3 days of daily activities of living, 7 to 14 days of postprocedure symptoms, and mucosal healing within 4 weeks. One subject in the first treatment group had the procedure aborted due to severe procedural pain. Conclusions: The study provides evidence of the safety and tolerability of anal RFA of 180° of contiguous mucosa in a single procedure and will allow future RFA efficacy studies in the treatment of anal dysplasia.Keywords
This publication has 25 references indexed in Scilit:
- HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issuesBMC Cancer, 2012
- Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagusGastrointestinal Endoscopy, 2011
- Durability of Radiofrequency Ablation in Barrett's Esophagus With DysplasiaGastroenterology, 2011
- Initial Experience with Topical Fluorouracil for Treatment of HIV-Associated Anal Intraepithelial NeoplasiaJournal of the International Association of Physicians in AIDS Care, 2011
- A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimodAIDS, 2010
- A feasibility and dosimetric evaluation of endoscopic radiofrequency ablation for human colonic and rectal epithelium in a treat and resect trialSurgical Endoscopy, 2010
- Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort StudyBritish Journal of Cancer, 2010
- Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected womenAIDS, 2009
- Human papillomavirus-related disease in people with HIVCurrent Opinion in HIV and AIDS, 2009
- High-Resolution Anoscopy Targeted Surgical Destruction of Anal High-Grade Squamous Intraepithelial Lesions: A Ten-Year ExperienceDiseases of the Colon & Rectum, 2008